(Q33579409)

28 July 2017

title

Interferon-beta1a: a once-weekly immunomodulatory treatment for patients with multiple sclerosis (English)

1 reference

28 July 2017

0 references

R Philip Kinkel

1

1 reference

28 July 2017

publication date

1 September 2006

1 reference

Expert Review of Clinical Immunology

28 July 2017

published in

1 reference

28 July 2017

volume

2

1 reference

28 July 2017

issue

5

1 reference

28 July 2017

page(s)

691-704

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.691

28 July 2017

1 reference

Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.691

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.691

Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.691

Cortical demyelination and diffuse white matter injury in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.691

Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.691

Magnetic resonance techniques for the in vivo assessment of multiple sclerosis pathology: consensus report of the white matter study group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.691

Clinical outcome measures and rating scales in multiple sclerosis trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.691

Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.691

Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.691

Serial contrast-enhanced magnetic resonance imaging in patients with early relapsing-remitting multiple sclerosis: implications for treatment trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.691

Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.691

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.691

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.691

New and emerging treatment options for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.691

Microarray analysis identifies interferon beta-regulated genes in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.691

A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.691

Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.691

A one-year study on the pharmacodynamic profile of interferon-beta1a in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.691

Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.691

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.691

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.691

The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.691

Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.691

Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.691

Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.691

Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.691

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.691

Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.691

Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.691

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.691

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.691

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.691

Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.691

Azathioprine and interferon beta(1a) in relapsing-remitting multiple sclerosis patients: increasing efficacy of combined treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.691

Mechanisms and current treatments of urogenital dysfunction in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.691

A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.691

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.691

21 January 2018

Identifiers

DOI

10.1586/1744666X.2.5.691

1 reference

28 July 2017

1 reference